News

Learn how and why East Indian Sandalwood Oil (EISO) is making international headlines as a unique, non-substitutable botanical drug candidate.

News

Santalis Pharmaceuticals Obtains FDA Allowance To Start A Phase 2 Clinical Study For The Treatment Of Mild To Moderate Atopic Dermatitis (AD)

Posted on

SAN ANTONIO–(MEDIA)–Following the recent start of its pediatric and adult Phase 2 clinical study for atopic dermatitis in Australia, Santalis Pharmaceuticals today announced it has obtained allowance from the U.S. Food and Drug Administration (FDA) to initiate a multi-center, placebo controlled, double blinded, Phase 2 efficacy and tolerability study for the treatment of mild to moderate atopic dermatitis (AD), also known as eczema. Read More Santalis Pharmaceuticals Obtains FDA Allowance To Start A Phase 2 Clinical Study For The Treatment Of Mild To Moderate Atopic Dermatitis (AD)

Supportive Data for the Use of Santalis Pharmaceuticals’ East Indian Sandalwood Oil (EISO) for the Treatment of Psoriasis is Presented at International Conference

Posted on

SAN ANTONIO–(MEDIA)–Data supporting the use of East Indian sandalwood oil (EISO) for the treatment of psoriasis was presented by Dr. Manju Sharma, of the Vancouver Prostate Centre, at the recent 7th Euro-Global Summit on Toxicology and Applied Toxicology held in Rome, Italy on 24 October, 2016. Dr. Sharma examined the ability of EISO to impact the psoriatic phenotype using organotypic […]Read More Supportive Data for the Use of Santalis Pharmaceuticals’ East Indian Sandalwood Oil (EISO) for the Treatment of Psoriasis is Presented at International Conference

Santalis Pharmaceuticals Obtains FDA Allowance To Start A Phase 2 Clinical Study For The Treatment Of Mild To Moderate Atopic Dermatitis (AD)

Posted on

SAN ANTONIO–(MEDIA)–Following the recent start of its pediatric and adult Phase 2 clinical study for atopic dermatitis in Australia, Santalis Pharmaceuticals today announced it has obtained allowance from the U.S. Food and Drug Administration (FDA) to initiate a multi-center, placebo controlled, double blinded, Phase 2 efficacy and tolerability study for the treatment of mild to moderate atopic dermatitis (AD), also […]Read More Santalis Pharmaceuticals Obtains FDA Allowance To Start A Phase 2 Clinical Study For The Treatment Of Mild To Moderate Atopic Dermatitis (AD)